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Abstract
In this study we have calculated a 3D structure of apoptin and through modeling and docking approaches, we show its
interaction with Bcr-Abl oncoprotein and its downstream signaling components, following which we confirm some of the
newly-found interactions by biochemical methods. Bcr-Abl oncoprotein is aberrantly expressed in chronic myelogenous
leukaemia (CML). It has several distinct functional domains in addition to the Abl kinase domain. The SH3 and SH2 domains
cooperatively play important roles in autoinhibiting its kinase activity. Adapter molecules such as Grb2 and CrkL interact
with proline-rich region and activate multiple Bcr-Abl downstream signaling pathways that contribute to growth and
survival. Therefore, the oncogenic effect of Bcr-Abl could be inhibited by the interaction of small molecules with these
domains. Apoptin is a viral protein with well-documented cancer-selective cytotoxicity. Apoptin attributes such as SH2-like
sequence similarity with CrkL SH2 domain, unique SH3 domain binding sequence, presence of proline-rich segments, and
its nuclear affinity render the molecule capable of interaction with Bcr-Abl. Despite almost two decades of research, the
mode of apoptin’s action remains elusive because 3D structure of apoptin is unavailable. We performed in silico three-
dimensional modeling of apoptin, molecular docking experiments between apoptin model and the known structure of Bcr-
Abl, and the 3D structures of SH2 domains of CrkL and Bcr-Abl. We also biochemically validated some of the interactions
that were first predicted in silico. This structure-property relationship of apoptin may help in unlocking its cancer-selective
toxic properties. Moreover, such models will guide us in developing of a new class of potent apoptin-like molecules with
greater selectivity and potency.
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Introduction
Aberrant expression of the Bcr-Abl oncogene is found with the
frequency of 695% of CML cases, and sporadically in other
malignancies [1,2]. Thus for therapeutic applications, especially
for CML treatment, Bcr-Abl is an attractive target for rational
drug design, although so far, only its tyrosine kinase domain has
been utilized. Bcr-Abl oncoprotein, contains a number of distinct
domains such as SH3, SH2, kinase domains, DNA binding
domains, actin-binding domains, nuclear localization signals,
nuclear export signal, and four proline-rich motifs that function
as binding sites for the adaptor proteins such as, Grb2 and CrkL
[2]. Several potent inhibitors have been developed and studied
extensively [3]. Imatinib is currently widely used for the treatment
of CML patients. Most chronic phase CML patients treated with
imatinib as first-line therapy, initially maintain excellent response.
However, failure of response occurs in advanced-stage CML
patients due to drug resistance caused frequently by mutations
within- or in the proximity to Bcr-Abl’s ATP-binding pocket.
Other types of changes have also been documented. For example,
CML stem cells obtained from some patients with imatinib
resistance, down-regulation the expression of the tumor suppressor
PTEN could be detected [4]. Although, the second-generation
tyrosine kinase inhibitors namely, dasatinib, nilotinib or bosutinib
are effective on most of the Bcr-Abl mutations, some p-loop
mutations or T315I substitution provide a very difficult resistance
to most of the Bcr-Abl kinase inhibitors currently in use [2,5,6].
Other therapeutic strategies besides small molecule approach
include the use of monoclonal antibodies [7].
Current understanding of resistance mechanisms include the
ability of cancer cells to remove drugs (drug efflux) by the different
transporters such as MDR1 (multidrug resistance protein 1) or P-
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transporter molecules such as SLC22A1 (solute carrier family 22
member 1), responsible for drug transport into the cell (drug
influx), or mutations altering the interaction of drug with its target.
These mechanisms however do not fully explain drug-resistance
observed in all instances. One of the possible reasons could be the
protein dynamics due to drug-protein binding (protein dynamics
due to folding, change in shape and size). It is known that the
kinase domain of Bcr-Abl is negatively regulated, in normal
situation, by cooperative combination of the SH3 and SH2
domain by internally engaging the SH2 domain [8,9]. Generally,
SH3 domains serve as modules that mediate protein-protein
associations along with SH2 domains and thus regulate cytoplas-
mic signaling. SH2 domains play important roles in (i) in cellular
communication, (ii) in a variety signal transduction pathways, and
(iii) in recognition of tyrosine-phosphorylated sites respectively. But
inappropriate communication or misreading of the phosphorylat-
ed site could lead to undesirable activation of pathways [10,11].
Negative regulation of Bcr-Abl by blocking these domains by
apoptin-inspired small molecule to control its oncogenic role
would be an attractive approach, as compared to conventional
targeted drug design [12]. In this study, we present a possible
alternative approach of inhibition of Bcr-Abl through surface
interaction of SH3 domain by the apoptin molecule rather than
binding to a narrowly-defined domain.
Apoptin has gained significant attention in recent years, both as
a lead for the development of cancer-specific therapeutics, and also
for its potential use as an indicator of cellular transformation
processes. Apoptin is a 13.6 kD viral protein encoded by the VP3
gene of Chicken Anemia Virus and is composed of 121 amino
acids [13,14]. It induces apoptosis independently of death receptor
pathways in a broad range of transformed and cancer cells.
Apoptin localizes in the nucleus in cancer cells, however in non-
transformed or primary cells it is localized to the cytoplasm
[15,16,17]. The cellular localization of apoptin is influenced by its
phosphorylation status at theronine-108. Phosphorylated T-108
inhibits nearby nuclear export signal, thus leading to nuclear
accumulation of apoptin [18,19,20]. Apoptin phosphorylation has
been proposed to be regulated by Akt-activated CDK-2 and PKC
kinase [21,22,23]. Thus, nuclear localization of apoptin and its
interaction with specific signaling proteins plays a crucial role in its
selective toxicity [19,20,24]. Highly organized recognition of
specific target binding partners by signaling proteins is an
important aspect of many cellular processes. The specificity of
these interactions is determined by the physical, structural and
chemical properties of the interacting proteins. Therefore, detailed
knowledge about the 3D structures of the involved proteins is
necessary to understand such interactions. Unfortunately, the 3D
molecular structure of apoptin revealing its precise structure-
function relationship has not yet been resolved by conventional
crystallography or NMR studies. Determination of the 3D
molecular structure requires that the molecule be in crystal form
suitable for X-ray crystallographic study or to be of less than
30 kD for accurate NMR study. In case of apoptin, the 3D
molecular structure could not be attained due to the inability of
the molecule to be crystallized, and the nature of the molecule to
stay in solution as globular multimers [25].
The alternative technique to study protein structures and to
predict interactions with other proteins is ‘homology modeling’
and ‘virtual protein docking’ experiments. This novel method to
identify the function of proteins, based directly on the sequence-to-
structure-to-function paradigm, is broadly known as ‘computa-
tional protein modeling’ [26]. While employing this approach, it is
possible to build the best-predicted structure of the protein from its
amino acid sequences (target) on the basis of known 3D structure
of related family members (templates). The ‘low resolution’ models
obtained by homology modeling provide essential information of
the spatial arrangement of important groups of residues.
Here we report for the first time, a simulated 3D model of
apoptin generated by using homology modeling as a backup
alternative to the conventional, crystallography- or NMR-based
methods. We then use the calculated structural coordinates of
apoptin to study its interaction with the 3D structure of CML-
associated oncoprotein Bcr-Abl. Furthermore, we biochemically
confirmed the accuracy of at least some elements of the model by
showing that the modeled interaction between apoptin and Bcr-
Abl indeed physically occurs between both proteins. We also
examined the pathways and interacting network from a global
perspective and experimentally validated some of the important
molecules.
Results
Apoptin is toxic to both Bcr-Abl positive and -negative
cells, and it inhibits Bcr-Abl phosphorylation/activation
The known domains of apoptin were designed and presented
(Fig. 1A) to understand its cytotoxicity in relation to its various
domains. As seen by the MTT assay performed on the
representative murine 32D
p210 cell line, Tat-apoptin efficiently
killed those cells as compared to control (Tat-GFP, Fig. 1B).
Furthermore, apoptin’s toxicity favorably compared to imatinib.
Evaluation of percentage cell survival was followed by the
examination of the phosphorylation status of Bcr-Abl in the
human leukemia cell line, K562 and the mouse cell line 32D
p210.
Tat-apoptin markedly inhibited phosphorylation of Bcr-Abl in
both cell lines. Inhibition of phosphorylation of Bcr-Abl was
evaluated by Western blotting (Fig. 1C) and quantified (Fig. 1D).
Identification of the SH3 binding domain of apoptin
SH3 Hunter software, a web based server, was used to identify
the SH3 binding domain of apoptin [27]. SH3- Hunter identified
the sequences, 81 to 86 (PKPPSK) as the SH3 binding domain.
SH3-binding domains have a consensus sequence:(-X-P-p-X-P-)
with 1 and 4 being aliphatic amino acids, 2 and 5 always-, and 3
sometimes being proline (data not shown) [28].
Apoptin colocalizes with nuclear phospho-Bcr-Abl and
physically interacts with it
We performed immunofluorescent imaging studies to evaluate
the subcellular localization of apoptin by comparison of the mouse
myeloid cell line, 32D
p210, stably transfected to express Bcr-
Abl
p210 with the Bcr-Abl non-expressing 32D
DSMZ cell line. In
32D
p210 cells transfected with GFP-apoptin (Tx, 32D
p210 and
32D
DSMZ cells transfected with GFP-apoptin), we observed the
nuclear localization of apoptin detected with anti-GFP concom-
itant to the Bcr-Abl localization detected with Bcr-Abl
p210 with
Cy3 conjugated secondary antibody (column 2, 3, topmost panel,
Fig. 2A). Colocalization of nuclear apoptin and phosphorylated
Bcr-Abl was confirmed in the merged image (column 4, topmost
panel, Fig. 2A). Column 1 in all three panels show DAPI stained
nuclei.
Several well-characterized SH3 domains were previously
identified as potential sites critical to ligand binding [29]. In
preliminary experiments, we performed an array-based screening
method (TransSignal SH3
TM Domain Array1) to identify the
interaction of apoptin with the SH3 domains of a known set of
proteins (data not shown). This highly stringent SH3 domain
interaction array screening indicated that apoptin strongly
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e28395Figure 1. Schematic representation of the primary structure and functional domains of apoptin, its cytotoxic potency and
inhibition of Bcr-Abl phosphorylation. (A) The SH3 binding domain is merged within NLS1 (amino acids, aa: 82–88). A pictorial representation of
apoptin sequences (UniProtKB/Swiss-Prot entry P54094), LRS=Lecine-Rich Sequence, NLS=Nuclear-Localization Signal, NES=Nuclear Export Signal.
(B) Cytotoxic activity of apoptin on Bcr-Abl positive 32D
p210 cells: 32D
p210 were grown in 96-well plates (10
4 cells per well). Cells (in triplicates for each
treatment) were treated with 1 mM Tat-apoptin, and Tat-GFP (negative control), or Imatinib for 0, 4, 8, 12, 18 and 24 h periods respectively. The
percentage of viable cells, as assessed by MTT assay indicates that apoptin and Imatinib are both toxic to 32D
p210 cells, and that apoptin’s cytotoxic
effect favorably compares to that of imatinib. Results are expressed as a percent of cell survival (mean 6 SD). (C) Apoptin inhibits Bcr-Abl
phosphorylation: K562 and 32D
p210 cells were treated with 1 mM Tat-apoptin, Tat-GFP (negative control) or 1 mM imatinib (positive control). Cells
were then harvested after 16 hrs and cell lysates were prepared. Representative Western blots show the expression levels of total and
phosphorylated Bcr-Abl; equal loading was checked by the loading control, eIF4E. The upper panel of bands shows the expression of K562 cells and
the lower panel shows the expression of 32D
p210 cells. Lanes from the left: (1) no-treatment control cell, (2) Tat-GFP treated cell, (3) imatinib treated
cell, and (4) Tat-apoptin treated cell respectively in both cell lines. (D) For quantitation, band intensities from immunoblots were scanned by Image
Quant software (version 5.2, Molecular DynamicsH). During quantitation, the imatinib expression data was omitted in order to enable visualization of
the apoptin effect with greater clarity. Bcr-Abl phosphorylation was significantly inhibited by apoptin. The quantitation data were normalized to the
loading control (eIF4E) and expressed as a ratio of phosphorylated to the total Bcr-Abl and presented as mean 6 SEM of three independent
experiments.
doi:10.1371/journal.pone.0028395.g001
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p210. (A) Indirect immunofluorescence showing the nuclear localization of Bcr-Abl.
32D
P210 and 32D
DSMZ cells were transiently transfected with GFP-apoptin (green) and subjected to (immuno)fluorescence staining and detection.
Apoptin localization was by GFP and Bcr-Abl was detected by staining with Bcr-Abl
p210 with Cy3 tagged (red) secondary antibody. Nuclei were co-
stained with DAPI (4, 6-diamidino-2-phenylindole: blue). Column 1 shows DAPI stained nuclei; columns 2 and 3 show the nuclear localization of Bcr-
Abl and apoptin. Column 4 shows the merged image of nuclear co-localized of Bcr-Abl
p210 and GFP-apoptin as small clusters (yellow). Abbreviations:
Tx=cells transfected with GFP-apoptin, No Tx=no transfection with GFP-apoptin. (B) To demonstrate apoptin and Bcr-Abl interactions, 5–10 mgo f
GST-apoptin was used in the ‘pull-down assay’. The interaction was tested either on 500 mg of total cell lysates from Bcr-Abl expressing 32D
p210 cells,
or on Bcr-Abl non-expressing 32D
DMSZ cells. Lanes from the left: (1) the pull-down products of Bcr-Abl in 32D
DMSZ extracts (negative control), (2)
32D
p210 extract (positive control), (3) 32D
p210 extract treated with glutathione-sepharose beads (beads control), and (4) 32D
p210 extract incubated
Apoptin Structure
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observation was further substantiated by ‘pull-down assay’ and
co-immunoprecipitation (Co-IP) studies using the Bcr-Abl
p210
stably expressing 32D
p210 cells and compared to the Bcr-Abl non-
expressing 32D
DSMZ cells (Fig. 2B). For the GST-pull down assay
recombinant GST and GST-conjugated apoptin were purified
from IPTG stimulated transformed bacterial clones harboring the
respective plasmids. The membrane was probed with anti-Bcr-Abl
primary antibody. A representative blot from such an experiment
shows the presence of Bcr-Abl (Lane 5) in the GST-Apoptin pull-
down product (220 kD, Fig. 2B). This 220 kD protein ‘pulled
down’ by apoptin, was confirmed by the presence of a similar band
in the lysates of 32D
p210 cells with stable expression of Bcr-Abl
p210.
This in vitro assay demonstrated apoptin interactions with Bcr-Abl.
Non-specific interactions in the absence of GST-Apoptin (beads
control, lane 4) were not detected. We further confirmed Bcr-Abl
and apoptin interactions by Co-IP when GFP-Apoptin was
transiently expressed in Bcr-Abl expressing 32D
p210 cells (Fig. 2C).
Apoptin interacts with Bcr-Abl via a specific motif
To identify the precise nature of apoptin and Bcr-Abl interaction
in CML cells, we mapped the sites on apoptin responsible for
interaction with specific region of Bcr-Abl
p210. The murine bone
marrow derived 32D
DMSZ, 32D
p210 cells and the human CML cell
line K562 were grown in appropriate media and transfected with
different apoptin mutant constructs (Materials and Methods,
[18,19]). The expression of these mutant derivatives of apoptin
tagged with an N-terminal GFP was verified by SDS-PAGE and
immunoblotting with mouse monoclonal anti-apoptin antibody.
Apoptin was immunoprecipitated by murine anti-GFP antibody
from lysates of transfected cells expressing various mutations of
apoptin with murine anti-GFP monoclonal antibody and the
protein complexes were analyzed to detect the presence of Bcr-
Abl
p210 by using rabbit monoclonal anti-Bcr antibody. Bcr-Abl
p210
was found in the immunoprecipitates of full-length apoptin and
apoptin derivatives that harbored amino acids from 74–100
(including the ‘Proline-rich sequence’: PRS), implying that this
region of apoptin is important for interaction with Bcr-Abl
p210 wt
(data not shown). Interestingly, in this model system, the mutants
Ala-108 and Glu-108 have a Thr-108 residue of apoptin
replacement by alanine or glutamine respectively; these replace-
ments render apoptin as non-phosphorylatable and are claimed by
someauthors to be non-toxicto cells [30]. Subsequently, the specific
interactions between full-length GST-conjugated apoptin and Bcr-
Abl
p210 or various SH-domain mutant-constructs of Bcr-Abl
expressed in 32D
DMSZ cells were studied (Fig. 2D). The mutants
included:(i) Bcr-Abl
p210DSH2: had anintactSH3, deleted SH2and
intact SH1, (ii) Bcr-Abl
p210DSH2 DSH3: had a deleted SH2,
deleted SH3 and intact SH1, (iii) Bcr-Abl
p210DSH3-R1053L: had a
deleted SH3, single amino acid (aa) substitution at SH2 and intact
SH1, and (iv) Bcr-Abl
p210P1013L-R1053L: had single aa substitu-
tion at the SH2 and SH3 domains respectively and intact SH1
domain. Mutants were selected according to their specific nature of
SH-domain mutations to probe if apoptin interacted with the SH3
domain of Bcr-Abl. Full length Bcr-Abl, and its derivates with intact
SH3-domain interacted with GST-Apoptin and were ‘pulled-down’
by glutathione sepharose beads, while other mutants lacking intact
SH3 domain failed to show such interaction.
Bioinformatics analysis of molecules known to interact
with (Bcr-)Abl
Global gene expression data for K562 cells was analyzed as
published [31]. Pathway analysis and visualization was performed
using the GenMapp and pathVisio bioinformatics tool [32,33].
The BioCarta pathway for the Bcr-Abl regulated genes in K562
cells was analyzed and visualized using PathViSio (Fig. 3A).
Another bioinformatics tool, ‘Ingenuity Pathways Analysis’ was
used to build and to identify the directly- or indirect interacting
network of molecules (Fig. 3B) [34]. Bioinformatics analyses were
validated experimentally for some of the molecules present in the
pathways and in the networks.
Apoptin down-regulates the Bcr-Abl kinase activity and
modulates the phosphorylation of downstream kinases
To study the down-stream effects of apoptin and Bcr-Abl
interaction, we examined the expression and phosphorylation
status of Bcr-Abl
p210 and other major down-stream Bcr-Abl targets
like STAT5, CrkL, c-Myc and Akt in mouse (32D
p210) and human
(K562) CML cell lines. In immunoblotting experiments, we
measured the phosphorylated and total proteins. The overall
results indicate that apoptin induced inhibition of Bcr-Abl
(auto)phosphorylation (Fig. 1C), down-regulated STAT5
(Fig. 3CD) and CrkL (Fig. 3GH) and activated Akt (Fig. 3EF).
These results are consistent with global gene expression pattern
observed in untreated K562 cells (Fig. 3AB). In all experiments, a
comparison was done with imatinib treated cells (positive control),
a known Bcr-Abl inhibitor and clinically-used CML-therapeutic.
We quantified the relative phophorylation level of Bcr-Abl
p210 by
immunoblotting with phospho-Bcr-Abl-specific antibodies and
thus we could assess the inhibition of activated Bcr-Abl by apoptin,
which was highly significant (p,0.01, 0.04) in both cell lines.
STAT kinases serve a dual role of signal transducers and
activators of transcription. Among the large family of over 30
STAT proteins, STAT5 has been identified as a key factor
involved in anti-apoptotic signaling and malignant transformation
in CML. Here we show that STAT5 phosphorylation was
markedly reduced in K562 cells following Tat-apoptin treatment,
with GST-Apoptin captured with glutathione-sepharose beads. (C) In order to detect apoptin and Bcr-Abl interaction by co-immunoprecipitation
assay, 32D
p210 cells were transiently transfected with GFP-apoptin (3 mg of pEGFP-apoptin plasmid for 2610
6 cells per transfection using
lipofectamine transfection reagent) and cell lysates were incubated with anti-Bcr-Abl antibody followed by immunoprecipitation by protein G-
sepharose beads; washed IP products were tested for the presence of apoptin (GFP-apoptin: 40 kDa) by immunoblot using anti-apoptin antibody.
Lanes from the left: 1 - GST-Apoptin (positive control), 2 - GFP-apoptin Co-IP from transfected 32D
p210 cells by anti-Bcr-Abl antibody, 3 - Co-IP
supernatant/immunodepleted fraction from transfected 32D
p210 cell lysates, 4 - 32D
p210 transfected with GFP (Co-IP, negative control), and 5 - Co-IP
from 32D
p210 cells without transfection (Co-IP, negative control). (D) The Abl SH3 domain in Bcr-Abl
p210 facilitates Bcr-Abl interaction with apoptin.
32D
DSMZ cells were transfected with various Bcr-Abl mutant constructs by lipofectamine using 3–4 mg purified plasmid DNA per 2610
6 cells. Specific
mutant clones of transfected cells were selected by G418. Pull-down assays were performed 7–10 days following the selection and expressed proteins
were detected by immunoblotting. The upper representative immunoblot shows various mutants of Bcr-Abl expressed in various 32D
DSMZ clones.
The lower immunoblot shows results of GST-apoptin pull-down assay. The Src-homology domain mutant of Bcr-Abl
p210 and GST-apoptin were used
in this ‘pull-down’ (.,) experiments using lysates from various Bcr-Abl mutant protein expressing 32D
DSMZ clones. The protein-protein complexes
were analyzed for apoptin interaction by immunoblotting with rabbit anti-Bcr antibody. As seen (lane 6–9), the presence of an intact SH3 domain in
the Bcr-Abl molecule is essential for its interaction with apoptin. Some degree of Bcr-Abl.,apoptin interaction was also seen in the Abl-SH3 domain
in Bcr-Abl, which was partially modified by single aa substitution (lane 10).
doi:10.1371/journal.pone.0028395.g002
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significant results (p,0.03) were obtained in Bcr-Abl
p210 express-
ing mouse cell line 32D
p210 (Fig. 3CD). Moreover, we also studied
the downstream consequences of Bcr-Abl inhibition by apoptin on
the phosphorylation status of CrkL. This 39 kD protein is involved
in b-integrin signaling and is a prominent substrate for activated
Bcr-Abl kinase [35]. We observed a significant (p,0.04) inhibition
of CrkL phosphorylation in K562 cells treated with 1 mM Tat-
apoptin for 16 hrs comparable to imatinib treated cells (quanti-
fication not shown for imatinib) (Fig. 3GH). Marked inhibition of
CrkL phosphorylation was also in Bcr-Abl
p210 expressing 32D
p210
(Fig. 3GH). For analysis of the pro-apoptotic effect of apoptin in
Bcr-Abl expressing cells, we examined its effect on the signaling
protein Akt and compared it to imatinib (Fig. 3EF). Interestingly,
although Akt is known mediator of cell survival, we observed a
marked augmentation of Akt phosphorylation 16 h after either
apoptin or imatinib treatment of K562 and 32D
p210 cells
(Fig. 3EF). It is possible that the activated Akt may still act in an
anti-apoptotic manner in Bcr-Abl expressing cells if re-located to
the nucleus as previously proposed [23,36,37]. Our results were
consistent with the global gene expression data for STAT5, CrkL,
and Akt (Fig. 3AB).
Figure 3. Visualization of pathways, interacting network, and validation of selected downstream regulators. (A) Bcr-Abl and its
downstream effectors are shown by BioCarta pathways. Global gene expression data of K562 leukemia cells was taken from public database,
analyzed, and visualized (GenMAPP). The expression values of signal log base e ratio (SLR) are shown outside the colored boxes. The software
generated color codes denote up-regulation (dark-red) and down-regulation (blue-green). (B) Direct and indirect interacting network associated with
Bcr-Abl was built utilizing global gene expression data and visualized by IPA. The up-regulated genes are shown in red and down-regulated genes are
shown as green. The gene expression values (SLR) are also shown. (C, E, G) Apoptin induced inhibition of Bcr-Abl phosphorylation leads to the down-
regulation of downstream regulators, STAT5, Akt, and CrkL respectively. K562 and 32D
p210 cells were treated with 1 mM Tat-apoptin, Tat-GFP
(negative control) and 1 mM imatinib (positive control) and cell lysates were prepared by harvesting cells after 16 h. Representative Western blots
(divided into upper and lower panels representing the K562 cells and the second panel represents the 32D
p210 cells) show the ratio of the expression
levels of phosphorylated and total STAT5 (D), Akt (F), and CrkL (H) respectively. In all the immunoblots, lane 1 from no-treatment control cells, lane 2
is from Tat-GFP treated cells, lane 3 is from Tat-apoptin treated cells respectively for both cell lines. STAT5 phosphorylation was significantly inhibited
by apoptin indicating that apoptin induced inhibition of Bcr-Abl phosphorylation decreases the activation of STAT5 through phosphorylation. On the
other hand, Akt phosphorylation was higher, indicating that apoptin induced Akt activation, as previously published. For CrkL, apoptin induced
inhibition of Bcr-Abl phosphorylation lead to the down-regulation of CrkL resulting in lower phosphorytion indicating that apoptin decreases the
activation of CrkL, a down-stream substrate of Bcr-Abl. For quantitation, band intensities were scanned by Image Quant software (version 5.2,
Molecular DynamicsH). During quantitation, imatinib expression data was omitted in order to enable greater visualization of the apoptin effect. The
quantitation data were normalized to the loading control (eIF4E/b-tubulin) and expressed as a ratio of phosphorylated to the total protein and
presented as mean 6 SEM of three independent experiments.
doi:10.1371/journal.pone.0028395.g003
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model of apoptin
In this part of the study, unknown 3D structure of apoptin was
approximated by a comparative- or homology protein modeling.
To this end, we used the protein sequence (target) based on the
known 3D structure of proteins with domains that have related
peptide sequences (Table 1). The 3D structures of several known
templates (Table 1) with identified partial homology to apoptin
were used to build the 3D structure. To build the apoptin model,
we used several modeling programs such as Modeller [38,39] and
DeepView [40], as well as project mode and the alignment mode
of Swiss Model web based server [40]. After numerous trials using
different templates, we were able to build the full-length apoptin
model. It is worth mentioning that model quality was different
when we used different chain of the same structure as a template.
To understand this difference in model quality, we superimposed
two chains in one of the templates (for example: PDB code: 1WLS,
chains A and B) and noticed the differences between two chains as
jugged by the RMS value (0.877 A ˚) when two chains were
superimposed. The difference in the RMS value may be due to the
missing residues in some cases and/or due to differences in
resolution between two chains. The Swiss Server Alignment mode
provided better results when multi-sequences were used. The T-
Coffee or ClustalW2 multiple sequence alignment tools [41] were
used to align a group of five or six sequences from a group of
templates (Table 1). Modeller [38,39] provided the best results.
One of the best models was used for further studies (Fig. 4BC).
The coordinates of this model are submitted as supporting
materials (Coordinates S1, S2, S3).
Subsequently, a Ramachandran plot was performed to verify
the quality of the model (Fig. 4D) [40,42,43,44]. The N-Ca and
Ca-C bonds in a polypeptide chain are relatively free to rotate.
These rotations are represented in the plot by the torsion angles
phi (w) and psi (y), respectively. The structure was examined for
close contacts between atoms for each of these conformations.
Atoms were treated as hard spheres with dimensions correspond-
ing to their van der Waals radii. Therefore, angles that cause
spheres to collide correspond to sterically disallowed conforma-
tions of the polypeptide backbone. Disallowed regions involve
steric hindrance between the side chain methylene group and
main chain atoms. This model of apoptin (aa:1–121), most
residues, about 81.8% of the residues (81 residues), were in the
most favored regions, 16.2% in the additional allowed regions,
2.0% in the generously allowed regions, and no residues were fall
in the disallowed regions according to Ramachandran plot
(Fig. 4D). According to Procheck, the overall G-factor was about
20.35. After examining the accuracy of the model, all atoms of the
molecule were locked, hydrogen atoms were added and molecular
mechanics (MM2) and molecular dynamic simulations was
performed at 1000 K for 50 ps simulation duration with 0.001
simulation time-step (ps). All theoretical calculations and visual-
ization were performed using ‘Scigress Explorer Ultra’ associated
with the ‘Gaussian03’ software [42,45,46].
This model was used to examine solvent accessible surface area
(Fig. 4E) to identify the surface (large patches, cream color, of
hydrophobic areas) of the protein that are involved in interactions
with other proteins and hydrophilic regions that involved in
hydrogen bonding, hydrogen bond acceptors (red color) and
hydrogen bond donors (blue color). This model was further used to
perform virtual docking experiments to examine and to under-
stand the interactions between apoptin and Bcr-Abl.
Virtual docking of Bcr-Abl and apoptin model
To examine protein-protein interaction between apoptin model
and the 3D structure (PDB code: 2ABL) of Bcr-Abl, molecular
docking experiments were performed using ClusPro [45,47] and
Hex [48] web based protein docking servers. The ClusPro
provided about ten structures. One of the lowest energy structures
(Fig. 5AB) was used for further analysis. All atoms are locked and
hydrogen atoms were added and energy optimization was
performed. Finally, interacting residues between two molecules
that are within 2.5 A ˚ of each other were identified and given in the
Table 2 and in Table 3 corresponding hydrogen bond distances
are presented.
Shape and sequence similarity of apoptin and the SH2
domain of CrkL
CrkL domains were identified using Prosite [49], a web based
server. Prosite identified SH2 (aa 14–102) and SH3 (aa: 123–183)
domains of CrkL. Sequence alignment of apoptin and the SH2
Table 1. List of template proteins used to build apoptin model.
PDB codes* PROTEINS
1WLS_A L-asparaginase I homologue from Archacea (pyrococcus horikoshii)
1OQY_A Human UV excision repair protein RAD23 homolog A
1Q9J_A Ml2640c from mycobacterium leprae
Apoptin PapA5, a phthiocerol dimycocerosyl transferase from Mycobacterium tuberculosis.
1E3I_A Murine alcohol dehydrogenase, class II
1E3L_A P47H mutant murine alcohol dehydrogenase, class II
2GYZ_A Neurotrophic factor artemin, isoform 3
2GYR_A Neurotrophic factor artemin, isoform 3
2GH0_C DNA-directed RNA polymerase alpha chain
1QZE_A UV excision repair protein RAD23 homolog A
1WNF_A PH0066 (L-asparaginase) from Archacea
2ASK_A Human artemin
2UYQ_A A viral protein encoded by the VP3 gene of Chicken Anemia Virus
*Data source: Protein Data Bank (RCSB-PDB).
doi:10.1371/journal.pone.0028395.t001
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the sequence of apoptin was somewhat similar (identical residues
21.7%, and similarity 40.6%) to that of SH2 domain of CrkL, and
apoptin’s proline-rich segment (aa: 81–88) was found to be within
this aligned region of SH2 domain. We then compared the shape
of known 3D structure (PDB code: 2EO3) of SH2 domain of CrkL
and apoptin model. Sequence alignment structural similarities are
shown in figure 6A, B, and C respectively. We also performed the
virtual docking experiments between the structure of SH2 domain
of CrkL and the structure of Bcr-Abl (PDB code: 2ABL).
Discussion
The 3D structure of apoptin has been unknown due to
numerous reasons (lack of a suitable crystals, multimerisation in
solution), furthermore apoptin modeling is challenging due to the
Figure 4. Sequence alignment and 3D model of Apoptin (aa: 1–121). (A) A representative sequence alignment between apoptin residues
and the residues of one of the templates from a group of templates (Table1) is shown. (B) Solid ribbon view of full-length (aa: 1–121) of 3D model for
apoptin and its amino and carboxyl terminals are shown. (C) Space filling view of apoptin model, showing the potential hydrophobic proline rich
interacting area (PKPPSK, aa: 81–86, pink colored region, top right) is shown. (D) Ramachandran plot showing the N-Ca and Ca-C bonds in the
apoptin polypeptide chain represented by the torsion angles phi (w) and psi (y); quality of the model was examined by this plot (all atoms are within
the allowed regions) and by the G-factors values (the overall value for G-factors is 20.35). (E) Solvent accessible surface area shows the regions of
hydrophobic (large cream colored region at the surface) where protein-protein interactions could occur and the hydrophilic regions that are involved
in hydrogen bonding, hydrogen bond acceptors (red color) and hydrogen bond donors (blue color). Additional information on apoptin structure
could be found in Coordinates S1, S2, S3.
doi:10.1371/journal.pone.0028395.g004
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model of apoptin by applying a comparative or homology protein
modeling approach despite low identity (about 31%) and similarity
(about 52%) of the templates. Figure 4A–C, and E shows the
sequence alignment of the templates, ribbon view, space filling full-
length model of apoptin, and Ramachandran plot, and solvent
accessible surface area respectively. This model was used to
virtually examine various binding interactions with Bcr-Abl by
performing virtual docking experiment between apoptin and the
X-ray crystal structure of Bcr-Abl (PDB code: 2ABL). First,
accessible surface area for apoptin was identified. As shown in
figure 4E, the large cream colored area is the hydrophobic region,
the sites for protein-interaction, purple-red areas and blue areas
are hydrophilic regions, purple-red indicates hydrogen bonding
acceptors (for example, C=O) and blue regions indicate hydrogen
bond donors (for example, N-H or O-H).
Using this model, we have been able to identify the nature of
interactions and hydrogen bonding between the residues of SH3
domain of Bcr-Abl and apoptin (Table 3). Subsequently, we have
experimentally verified the observed interaction between apoptin
and the SH3 domain of Bcr-Abl oncoprotein. In this model
system, 13 aa (Fig. 5B, red) of SH3 domain of Bcr-Abl are
approximated within 2.5 A ˚ of apoptin and 13 aa (Fig. 5B, light-
green) of apoptin are within 2.5 A ˚ of Bcr-Abl residues.
Interestingly, some of the proline rich PxxP sequences (aa: 81–
86, QPKPPSKKR) (Fig. 5AB) are involved in these interaction
among other nearby residues and at least five pairs of direct
hydrogen bonding are possible between them (Table 2). This low-
Figure 5. Modeled interactions between apoptin and Bcr-Abl. (A) Shows the interaction between apoptin and the SH3-domain of Bcr-Abl
(solid ribbon view, showing the two terminals of two proteins) obtained by performing virtual docking experiment between apoptin model and the
X-ray structure of Bcr-Abl-SH3 domain (PDB: 2ABL). (B) Shows the space filling docking view of the interactions between apoptin (pink) and the SH3-
domain of Bcr-Abl (blue), the 13 residues (red) of Bcr-Abl and 13 residues (light blue) of apoptin that are within 2.5 A ˚ to each other; some of the
proline-rich (PxxP) SH3-binding residues (Table 2) are present and at least five direct hydrogen bonding are possible in between them (Table 3).
Additional information on apoptin interaction with BcrAbl could be found in Coordinates S4, S5, S6.
doi:10.1371/journal.pone.0028395.g005
Table 2. Interacting amino acid residues of apoptin and Bcr-
Abl.
Apoptin Interacting residue BCR-ABL residue
Thr8 Lys29
Lys82
* Glu68
Pro83* Ser66, Glu68
Lys86* Pro63
Lys87* THR62
Thr108 Ser71
Arg111 His74
Pro112 His74
Thr114 Tyr84, Leu85
Ala115 Val77
Lys116 His74
Arg118 Ser 78, Glu100
Ile119 Pro76
*The SH3 interacting amino acids in the proline rich PxxP region of apoptin are
marked as bold.
doi:10.1371/journal.pone.0028395.t002
Table 3. Amino acid residues forming hydrogen bond
between apoptin and Bcr-Abl.
Apoptin residue BCR-ABL Hydrogen Bond distance (A ˚)
Thr8 Lys29 1.983
LYS82
* Glu68 1.86
Lys86* Glu98 2.072
Lys116 His74 1.912
Arg118 Glu100 2.102
*Hydrogen bonding forming residues between the Bcr-Abl and the proline rich
PxxP region of apoptin are shown in bold.
doi:10.1371/journal.pone.0028395.t003
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between Bcr-Abl and apoptin and it helps us to explain the
probable mode of action; moreover, our experimental pull-down
assay’ and co-immunoprecipitation studies confirm occurrence of
those interactions in cell nuclei.
We not only show for the first time, that Tat-apoptin, a cell-
penetrating conjugate of apoptin strongly binds to the SH3
domain of Bcr-Abl, but also it modifies the phosphorylation status
and thus the activity of Bcr-Abl, and several of its downstream
targets. These changes lead to the anti-proliferative effect and
induction of intrinsic apoptotic pathways in rapidly dividing CML
cells. Using human CML cell line, K562 and Bcr-Abl
p210
expressing murine cell line 32D
p210 as models, we observed that
these cells are significantly responsive to apoptin. These highly
proliferating human and murine cell lines have a high cytoplasmic
Bcr-Abl
p210 pool and thus the cell culture condition mimic the
blast crisis stage of CML. Furthermore, as in CML, the central
mitogenic Ras-MAPK cascade is also activated, similarly as in our
model cell lines. Our findings corroborate well with previous
studies, by Kardinal and colleagues, involving a similar approach
directed towards the Grb2-SoS-Ras-MAP kinase (Erk) pathway
[50]. In these experiments, small, high affinity peptides blocking
the N-terminal SH3 domain of Grb2 were applied. Their results
indicate that peptide based inhibitor of Bcr-Abl kinase or its down-
stream targets could be valuable anti-CML tool if combined with
conventional cytotoxic therapy [50]. We have also observed that
apoptin-derived peptides capable of interaction with SH3 domain
are toxic against Bcr-Abl expressing cells (data not shown). We
Figure 6. Sequence alignment and interactions between apoptin and adopter proteins CrkL, Akt1 and STAT5. Space filling views and
similarity in sequences between apoptin and the SH2-domain of the adopter protein CrkL (A), apoptin’s SH3-binding domain residues (B), 81 to 86
(PKPPSK), are within the SH2-domain of CrkL (C). In addition, the similarity in sequences between apoptin and the adopter proteins Akt1 (D) and
STAT5 (E) suggesting that apoptin might directly interact in the CrkL, Akt1 and STAT5 interacting sites in addition to the SH3-binding domain of Bcr-
Abl and could block further propagation of survival and proliferation signaling.
doi:10.1371/journal.pone.0028395.g006
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was effective both against Bcr-Abl positive and also Bcl-Abl
negative cells. We thus hypothesize that apoptin-based therapeu-
tics would be not only more effective, but have the additional
advantage that they would be less prone to the development of
resistance.
Activation of Bcr-Abl is critical for the development of CML.
Different downstream molecules and pathways such as the Grb2-
Ras-Raf-Mek1/2 Erk pathway, the PI3 kinase pathway involving
Gab2 [51,52,53,54,55], the Jak2-STAT3 pathway [56,57], and
the Bcr-Abl-STAT5 pathway [58,59] are implicated as shown in
figure 3A. Using bioinformatics approaches, we visualize the
relationship between these component molecules and pathways
using global gene expression data. A comprehensive analysis of
molecular interactions of Bcr-Abl target molecules that are either
directly (solid lines or solid lines with arrows) or indirectly (broken
lines or broken lines with arrows) involved are shown in an
interaction network (Fig. 3B). Interrelationship between molecules
is clearly visualized their activated (pink color) or repressive (green
color) states. In this figure, expression values are also shown. As
shown in diagram 3A, the network of genes and proteins is very
complex and in the context of drug design it is essential to consider
these interrelationships to avoid drug toxicity.
In our previous studies, we have shown that direct apoptin-Akt
interaction initiates nuclear trafficking of Akt. Interestingly,
nuclear Akt, instead of activating an anti-apoptotic response
initiates apoptosis by a process that is only partially understood
[36]. Our observation corroborates well with recent data from
other studies, showing that Akt inhibitors have been only
moderately successful in experimental cancer therapy [60].
Furthermore, similar to the earlier observed nuclear transfer of
Akt, we have also observed the nuclear transport of apoptin-
interacting protein Bcr-Abl. We hypothesize that nuclear re-
location of Bcr-Abl may markedly affect its biologic properties.
The adaptor proteins CrkL forms a complex with Bcr-Abl
leading to Bcr-Abl–dependent phosphorylation of CrkL and
subsequent phosphorylation of c-Cbl may contribute to Bcr-Abl
dependent activation of PI3 kinase [61]. Multiple downstream
targets of PI3 kinase have been identified. But apoptin interaction
might block complex formation between the adapter protein CrkL
and Bcr-Abl. Nuclear localization of apoptin is essential to block
the complex formation between Bcr-Abl and CrkL. We have
examined the nuclear localization of apoptin as shown Figure 2A.
As previously mentioned, apoptin is a cytoplasmic molecule but
nuclear localization occurs upon phosphorylation at Thr108 in
transformed cells, thus in CML-cells it is predominantly nuclear.
These interactions and trans-activation of CrkL and c-Crk II by
activated Bcr-Abl kinase and their functional consequences are
well documented [35,62]. In the current study, we demonstrated
for the first time that apoptin inhibits phosphorylation of CrkL in
Bcr-Abl expressing cells. This observation indicates that apoptin
can indirectly affect growth-supportive role of phosphorylated
CrkL by inhibiting Bcr-Abl kinase. Overall, these observations
signify apoptin as a negative-modulator of Bcr-Abl kinase activity,
and indirectly, of the multiple cell proliferation and anti-apoptotic
pathways that are fuelled by Bcr-Abl. We also consistently
observed the activation of Akt upon apoptin and/or imatinib
treatment in Bcr-Abl expressing cells. Akt is a downstream target
for Bcr-Abl kinase and known to interact with apoptin. However it
also functions independently of Bcr-Abl, for example, it is one of
the key effectors of the PI3-K/PDK1-2 pathway upon cell
membrane triggering. Beside its pro-survival function, activated
Akt if located in the nucleus, will promote cell death rather than
cell survival [23,36,37].
STATs act as regulators of cell proliferation [63]. The N-
terminal regulatory region of Abl protein contains the SH2 and
SH3 domains which are important for the regulation of activity in
vivo [64]. We have previously reported that apoptin productively
interacts with the SH3 domain of p85 regulatory subunit of PI3-K
[18]. In the current study, we report for the first time that apoptin
inhibits STAT5 activation in Bcr-Abl expressing cell lines.
Furthermore, since STAT5 also regulates the Bfl-1 family gene
A1 that reportedly collaborates with c-myc and is required for Bcr-
Abl transformation [65], this observation strongly supports the role
of apoptin as a proliferation inhibitor of CML cells.
Different components of the Bcr-Abl downstream pathways are
involved in the pathogenesis of CML and are highly active
compared to normal cells. Hyperactivation of STATs, Ras-MAPK
or CrkL-integrin pathways lead to the development of character-
istic CML pathologic features. Apoptin affects many of these
signaling events, and thus it is well suited for targeting the cellular
signaling environment of Bcr-Abl expressing cancer cells. In
addition, apoptin is a good candidate to serve as a model/lead
molecule for the development of smaller peptides or peptidomi-
metics that would target multiple cell proliferation and anti-
apoptotic pathways. This may be of advantage also for CML-
treatment because advanced highly mutated CML-cells may no
longer solely rely on Bcr-Abl as the driver of cell proliferation
(hence, acquired resistance to Imatinib). Apoptin acts on multiple
targets related to cell proliferation by blocking their association
with Bcr-Abl rather than binding. Thus, this is an alternative
approach to the conventional target based rational drug design to
block the interactions of adapter molecules rather than binding a
small molecule to the active site. When a small molecule diffuses
into a macromolecule, it alters the shape and size of the
macromolecule leading to its conformation change. These changes
in shape, size, and dynamics could lead to the activation/
deactivation of undesired bio-molecules that in turn may yield
detrimental effects.
To improve the potency and specificity of small apoptin-like
peptides, designing new small molecules with proper shape,
number of proline residues in appropriate positions, and capability
of nuclear trafficking is essential. To avoid undesirable drug
effects, repetitive evaluation of potency, examination of global
gene expression, and extensive bioinformatics analysis are
indispensable until a drug-like molecule with desired properties
is achieved. Present study, model-structure-function relationship,
provides such opportunities to design next generation of apoptin-
like molecules with desired properties. We are aware of limitations
of computational modeling of protein structure. However since we
are able to confirm by biochemical methods the predicted
intermolecular interactions, we are convinced that the provided
model is highly accurate.
Materials and Methods
Three-dimensional/3D modeling
The homology modeling approach was used to generate 3D
structures of apoptin, a viral protein encoded by the VP3 gene of
Chicken Anemia Virus that is composed of 121 amino acids
(13.6 kDa). The crystal structure coordinates of the PDB id 1WLS,
L-asparaginase from the hyper-thermophilic archaeon Pyrococcus
horikoshii was used as one of the templates. The sequence of apoptin
has about 31% identity and about 52% similarity with the
sequence of the PDB id 1WLS. As mentioned earlier, different
approaches were used to build the apoptin model. For alignment
mode (Swiss Model web based server), five sequences, including
apoptin, with known 3D structures were aligned using T-Coffee
Apoptin Structure
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e28395Multiple Sequence Alignment Tool [41] and then submitted for
model building. For project mode (Swiss Model web based server),
the DeepView Tool [40] was used to align sequences of known
structure, then apoptin sequence was threaded to the crystal
structure of PDB id 1WLS and then submitter for model building.
Modeller [38,39] a web-based server was also used in model
building. Several other computer programs [42,43,44,66] were
used to build and process the apoptin model using 121 amino acids
sequence. Several models building were performed using different
templates and accuracy was examined. One of the best models was
used for further studies. All other calculations including molecular
dynamic simulation and visualization of 3D structure were
performed using Scigress Explorer Ultra [46]. After building the
3D model of apoptin, all atomic positions are locked and required
hydrogen atoms were added to the backbone structure of the
apoptin molecule and performed ‘molecular mechanics’ calcula-
tions and then performed molecular dynamics simulation at
1000 k for 50 ps for further optimization. One of the best apoptin
models was used to examine the solvent accessible surface area. A
docking file with pdb extension of apoptin molecule was prepared
without hydrogen atom to perform molecular docking p17exper-
iments to examine the interaction between apoptin model and the
Bcr-Abl oncoprotein using 3D structure of the protein (PDB code:
2ABL).
Validation of 3D Model
After building the 3D apoptin model, the Protein Structure &
Model Assessment Tools [42,43,44] was used to verify the quality
of the apoptin model. This tools is capable of verifying a number
of aspects of model qualities such as (1) Local Model Quality
Estimation (anolea atomic mean force potential, empirical force
field, composite scoring function for model quality estimation); (2)
Global Model Quality Estimation (all-atom distance-dependent
statistical potential); (3) Stereochemistry Check (protein structure
verification, stereochemical quality check; min. resolution 2.5 A ˚)
and (4) Structural Features (secondary structure, geometrical
features, and solvent exposure assignment, analysis of protein
structure motifs). Based on these assessment results, model quality
was evaluated according to the Ramachandran plot and the amino
acid residues in the allowed, disallowed region and overall G-
factor.
Molecular Docking of Apoptin model to the 3D Structure
of SH3 domain of Bcr-Abl
Three (Hex, ClusPro, and AutoDock) computer programs
[45,48] were used to perform the docking experiments. All
docking programs required two separate input files for the two
molecules, apoptin model and 3D structure of SH3 domain of Bcr-
Abl, without hydrogen atoms with pdb extension. The ClusPro
provides greater and accurate information. Several apoptin models
were used to perform docking experiments using ClusPro docking
server. After the docking experiments, the ClusPro server provided
about 10 structures. The lowest energy docking structure was used
for further studies. After the docking experiments, all other
modeling and calculations were performed using DeepView and
Scigress Explorer Ultra. All atomic positions of the lowest energy
docking structures are locked and required hydrogen atoms were
added to the structures and performed ‘molecular mechanics’
calculations to minimize the energy for the added hydrogen atoms.
This minimize structure was used to examine and to identify the
interacting residues between apoptin and the Bcr-Abl molecules.
Hydrogen bonding of the interacting residues between the two
proteins was also examined. These molecular interactions were
further verified biochemically.
Pathway, Interacting Network using and Global Gene
Expression data
Pathways and gene/protein interacting networks were exam-
ined from a global prospective using bioinformatics tools and
microarray gene expression data, such as ‘GenMapp’ and
‘Ingenuity Pathway Analysis’. We used the publicly available gene
expression data from K562, a leukemia cell line expressing Bcr-
Abl. Two input files specific for each bioinformatics tool were
prepared. Expression of some of important molecules was
validated experimentally in the presence and absence of apoptin.
Cell lines, plasmids, Cell death and cell proliferation
assays, antibodies and reagents
All cell culture media and supplements were from Gibco BRL.
32D
DSMZ and 32D
p210wt:b3:a2/e13:a (denoted as 32D
p210) [67]
Bcr-Abl variant were grown in RPMI-1640 cell culture medium
500 ml supplemented with 20% FBS (Hyclone), 0.05 g penicillin/
streptomycin, 10 mM HEPES (2-(4-hydroxyethyle)-1-piperaziny-
l)ethanolsulfonsa ¨ure), 2 mM L-Glutamine, 0.13 mM L-Asparagin,
0.05 nM 2-Mercaptoethanol, 1 mM Na-Pyruvate, and 3 ml 1006
non-essential amino acids. 32DDSMZ cells are strictly dependent on
murine interleukin 3, so the media was supplemented with 10%
supernatant from WEHI-3B cells [67]. The human CML cell line
K562 (ATCCH # CCL-243
TM) was cultured in ATCC recom-
mended Iscove’s modified Dulbecco’s medium with 4 mM L-
glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 10%
FCS (v/v) and antibiotics [68,69]. All cells were grown at 37uC
with 5% CO2 in a humidified incubator and maintained in a
logarithmic growth. The following plasmids were used: GFP, GFP-
Apoptin (apoptin cloned into pEGFP-C1 vector, Clontech), GST,
GST-Apoptin (apoptin cloned into PGEX-2T vector, Amersham
Biosciences), apoptin mutants were previously described [19]. The
p210Bcr-Abl mutants (kind gift from Dr. T. Skorski, Temple
University, USA), DSH2 (deletion of the SH2 domain),
DSH3+DSH2 (deletion of both the SH3 and the SH2 domains),
DSH3+R1053L (deletion of the SH3 domain and single aa
substitution in the SH2 domain) and P1013L+R1053L (single aa
substitutions in the SH3 and SH2 domains), cloned in
pSRaMSVtkneo vector as described [70]. Plasmids were propa-
gated either in BL21(DE3)pLysS or DH5a E. Coli strains, upon
transformation by CaCl2 chemical method. Plasmid isolation
(positive clones) was done using Qiagen Maxi-prep kits. Cell
proliferation was assessed by MTT assay, and cell death was
measured by propidium iodide uptake as previously described
[71].
Chemicals and antibodies were purchased from Sigma-AldrichH
Inc. (Sigma, Oakville, ON, Canada) AbcamH Inc. (Cambridge,
MA, USA) or Cell Signaling TechnologyH, Inc. (Danvers, MA,
USA). The following antibodies were used: murine/rabbit anti-
Bcr-Abl/anti-Bcr (monoclonal: AbcamH Inc.), murine anti-Akt
(monoclonal) and the murine monoclonal anti-apoptin antibody
(kind gift from Dr. D. Jans, Australia).
Transfection of mammalian cells
Different mammalian primary and cancer cell lines were
transfected with the desired plasmids by Lipofectamine
TM2000
(InvirogenH Canada Inc. Burlington, Ontario, L7P 1A1) reagent.
The cells were plated in an antibiotic free medium 24 h prior to
transfection and plasmid DNA was added to 100 ml of medium in
a tube at the recommended concentrations (typically 2 mg for a 12
well plate and 5 mg for a 6 well plate) at the time of transfection.
The Lipofectamine reagent (5 ml for 12 well and 10 ml for 6-well
plate) was diluted in 100 ml of medium in a second tube. Next, the
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then incubated for 20 min at room temperature to allow the
formation of DNA liposome complexes. Following the incubation,
the DNA-lipid mixture was gently added directly to the cells that
had previously been rinsed with PBS and replaced with fresh
medium.
GST-pull down assay and protein identification, co-
immunoprecipitation (Co-IP), Western blotting
The GST and the recombinant GST-apoptin proteins were
purified according to the manufacturer’s protocol using glutathi-
one sepharose beads (Amersham BiosciencesH). GST-pull down
assay was performed to detect the interacting partners of apoptin.
Briefly, either purified GST or GST-apoptin along with total
32D
p210 or K562 cell lysate (by sonification) were immobilized on
glutathione sepharose beads overnight at 4uC in IP buffer with
protease and phosphatase inhibitors (50 mM Tris-HCl pH 8.0,
NaCl 150 mM, ND-40 0.5%, EDTA 1 mM, PMSF 1 mM, NaF
10 mM, Na3VO4 1 mM, b-glycerophosphate 25 mM). Beads
were washed at least six times with ice-cold lyses buffer and the
bound proteins were detected by Western blotting.
For Co-IP experiments, 2–5 mg of antibody was added to 100–
500 mg of cell lysate and incubated (4 hr at 4uC) and then 100 ml
of equilibrated 50% protein-G Sepharose beads (Amersham
Pharmacia BiotechH) were added to the protein-antibody immune
complexes and incubated (1 h at 4uC). Beads were washed (66)
with lyses buffer and after the final wash, beads were suspended in
SDS sample buffer and resolved on SDS-PAGE gel, and the Co-
IPed protein was detected by Western blotting. Other Western
blotting experiments were performed as previously reported
[72,73,74]. Briefly, about 30 mg protein lysates were resolved by
SDS PAGE, transferred to PVDF-membrane (Amersham Bios-
ciencesH), membrane blocked (5% non-fat dry milk powder/tris-
buffered saline with 0.25% v/v Tween-20 5% bovine serum
albumin, BSA). Membranes were washed and incubated with an
appropriate secondary antibody conjugated with horseradish
peroxidase (HRP) for 45 min at room temp and detected by
using enhanced chemiluminescent (ECL) staining (Amersham
BiosciencesH).
Immunocytochemistry and fluorescent imaging
Cells were allowed to attach overnight, transfected with
appropriate plasmids and after 16–18 h of incubation cells were
collected, washed with PBS, and fixed in 4% w/v paraformalde-
hyde/PBS. Thin smear of cells was prepared on standard
microscope glass slides and air-dried. Cells were permeabilized
(0.1% triton X-100/PBS), blocked (5% BSA/PBS, 1 h) and
incubated overnight at 4uC with an appropriate primary antibody,
followed by incubation with Cy3 or FITC conjugated secondary
antibody. Slides were mounted with VectashieldH containing
DAPI. Fluorescence signals were acquired using Zeiss fluorescent
microscope and analyzed by Zeiss Axiovision (Version 3.1)
software.
Bcr-Abl multiplex kinase assays
The phosphorylation status of Bcr-Abl, STAT5, CrkL and Akt
were measured by scanning the signal strength of phosphorylated
proteins on Western blot membranes. Kinase reaction was
performed in K562 and 32D
p210 cells by overnight (16 h)
incubation with Tat-apoptin (test), ImatinibH (positive control)
Tat-GFP, or no treatment (negative controls) and cell extracts
were resolved by SDS-PAGE (10%) and detected by immuno-
blotting using respective phospho-specific antibodies or antibodies
detecting both phosphorylated and non-phosphorylated kinase. A
high-resolution scanner (STORM 860: Molecular DynamicsH:
Amersham Pharmacia Biotech) was used to scan the immunoblot
membranes after ECL detection and individual band intensities
were measured by Image Quant (Version 5.2) software (Molecular
DynamicsH). Band intensities were normalized to the respective
loading controls and expressed as a ratio of measured values for
phosphorylated proteins versus total protein bands.
Statistical Analysis
Unless stated otherwise, all normalized band intensity data were
statistically analyzed by student’s t test assuming equal variance using
MicrosoftH Excel software. The variance patterns in each set of
data were previously checked by ANOVA from Excel data
analysis tool package.
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